New HIV vaccine trial launches in southern africa
NCT ID NCT06617091
First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 26 times
Summary
This early-stage trial is testing a new HIV vaccine called GRAdHIVNE1 in 120 healthy adults, both with and without HIV, in Southern Africa. The vaccine uses a harmless gorilla virus to deliver HIV protein fragments, aiming to train the immune system to fight the virus. The main goal is to check safety and see if the vaccine triggers a strong immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AHRI
RECRUITINGMtubatuba, KwaZulu-Natal, South Africa
-
DTHF
RECRUITINGCape Town, Western Cape, South Africa
-
Mutala
RECRUITINGHarare, Harare, Zimbabwe
Conditions
Explore the condition pages connected to this study.